Afinitor Disperz — CareFirst (Caremark)
relapsed or refractory classic Hodgkin lymphoma
Initial criteria
- Subsequent treatment
- Single-agent therapy
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months